[1]
|
International Diabetes Federation (2017) IDF Diabetes Atlas. 8th Edition, International Diabetes Federation, Brussels. http://www.diabetesatlas.org
|
[2]
|
Al Dawish, M.A., Robert, A.A., Braham, R., Al Hayek, A.A., Al Saeed, A., Ahmed, R.A., et al. (2016) Diabetes Mellitus in Saudi Arabia: A Review of the Recent Literature. Current Diabetes Reports, 12, 359-368. https://doi.org/10.2174/1573399811666150724095130
|
[3]
|
American Diabetes Association (2020) 9. Pharmacologic Approaches to Glycemic Treatment: Standards of Medical Care in Diabetes—2020. Diabetes Care, 43, S98-S110. https://doi.org/10.2337/dc20-S009
|
[4]
|
Davies, M.J., D’Alessio, D.A., Fradkin, J., et al. (2018) Management of Hyperglycemia in Type 2 Diabetes, 2018. A Consensus Report by the American Diabetes Association (ADA) and the European Association for the Study of Diabetes (EASD). Diabetes Care, 41, 2669-2701. https://doi.org/10.2337/dci18-0033
|
[5]
|
Garber, A.J., Handelsman, Y., Grunberger, G., et al. (2020) Consensus Statement by the American Association of Clinical Endocrinologists and American College of Endocrinology on the Comprehensive Type 2 Diabetes Management Algorithm— 2020 Executive Summary. Endocrine Practice, 26, 107-139. https://doi.org/10.4158/CS-2019-0472
|
[6]
|
U.S. Food & Drug Administration (2009) Prescribing Information: BYETTA® (Exenatide) Injection. https://www.accessdata.fda.gov/drugsatfda_docs/label/2009/021773s9s11s18s22s25lbl.pdf
|
[7]
|
U.S. Food & Drug Administration (2016) Prescribing Information: ADLYXIN® (Lixisenatide) Injection, for Subcutaneous Use. https://www.accessdata.fda.gov/drugsatfda_docs/label/2016/208471orig1s000lbl.pdf
|
[8]
|
U.S. Food & Drug Administration (2018) Prescribing Information: BYDUREON®(Exenatide Extended-Release) for Injectable Suspension, for Subcutaneous Use. https://www.accessdata.fda.gov/drugsatfda_docs/label/2018/022200s026lbl.pdf
|
[9]
|
U.S. Food & Drug Administration (2020) Prescribing Information: OZEMPIC® (Semaglutide) Injection, for Subcutaneous Use. https://www.accessdata.fda.gov/drugsatfda_docs/label/2017/209637lbl.pdf
|
[10]
|
U.S. Food & Drug Administration (2014) Prescribing Information: TANZEUM® (Albiglutide) for Injection, for Subcutaneous Use. https://www.accessdata.fda.gov/drugsatfda_docs/label/2014/125431s000lbl.pdf
|
[11]
|
U.S. Food & Drug Administration (2020) Prescribing Information: TRULICITY® (Dulaglutide) Injection, for Subcutaneous Use. https://www.accessdata.fda.gov/drugstfda_docs/label/2017/125469s007s008lbl.pdf
|
[12]
|
U.S. Food & Drug Administration (2017) Prescribing Information: VICTOZA® (Liraglutide) Injection, for Subcutaneous Use. https://www.accessdata.fda.gov/drugsatfda_docs/label/2017/022341s027lbl.pdf
|
[13]
|
Htike, Z.Z., Zaccardi, F., Papamargaritis, D., Webb, D.R., Khunti, K. and Davies, M.J. (2017) Efficacy and Safety of Glucagon-Like Peptide-1 Receptor Agonists in Type 2 Diabetes: A Systematic Review and Mixed Treatment Comparison Analysis. Diabetes, Obesity and Metabolism, 19, 524-536. https://doi.org/10.1111/dom.12849
|
[14]
|
Witkowski, M., Wilkinson, L., Webb, N., Weids, A., Glah, D. and Vrazic, H. (2018) A Systematic Literature Review and Network Meta-Analysis Comparing Once-Weekly Semaglutide with Other GLP-1 Receptor Agonists in Patients with Type 2 Diabetes Previously Receiving 1-2 Oral Antidiabetic Drugs. Diabetes Therapy, 9, 1149-1167. https://doi.org/10.1007/s13300-018-0424-2
|
[15]
|
Gentilella, R., Pechtner, V., Corcos, A. and Consoli, A. (2019) Glucagon-Like Peptide-1 Receptor Agonists in Type 2 Diabetes Treatment: Are They All the Same? Diabetes/Metabolism Research and Reviews, 35, e3070. https://doi.org/10.1002/dmrr.3070
|
[16]
|
Hughes, S. and Neumiller, J.J. (2020) Oral Semaglutide. Clinical Diabetes, 38, 109-111. https://doi.org/10.2337/cd19-0079
|
[17]
|
Cosentino, F., Grant, P.J., Aboyans, V., et al. (2020) 2019 ESC Guidelines on Diabetes, Pre-Diabetes, and Cardiovascular Diseases Developed in Collaboration with the EASD. European Heart Journal, 41, 255-323. https://doi.org/10.1093/eurheartj/ehz486
|
[18]
|
Jain, A.B., Ali, A., Gorgojo Martínez, J.J., et al. (2021) Switching between GLP-1 Receptor Agonists in Clinical Practice: Expert Consensus and Practical Guidance. European Heart Journal, 75, e13731. https://doi.org/10.1111/ijcp.13731
|
[19]
|
Almandoz, J.P., Lingvay, I., Morales, J. and Campos, C. (2020) Switching between Glucagon-Like Peptide-1 Receptor Agonists: Rationale and Practical Guidance. Clinical Diabetes, 38, 390-402. https://doi.org/10.2337/cd19-0100
|
[20]
|
Buse, J.B., Nauck, M., Forst, T., et al. (2013) Exenatide Once Weekly versus Liraglutide Once Daily in Patients with Type 2 Diabetes (DURATION-6): A Randomised, Open-Label Study. The Lancet, 381, 117-124. https://doi.org/10.1016/S0140-6736(12)61267-7
|
[21]
|
Pratley, R.E., Nauck, M.A., Barnett, A.H., et al. (2014) Once-Weekly Albiglutide versus Once-Daily Liraglutide in Patients with Type 2 Diabetes Inadequately Controlled on Oral Drugs (HARMONY 7): A Randomised, Open-Label, Multicentre, Non-Inferiority Phase 3 Study. The Lancet Diabetes & Endocrinology, 2, 289-297. https://doi.org/10.1016/S2213-8587(13)70214-6
|
[22]
|
Nauck, M., Rizzo, M., Johnson, A., Bosch-Traberg, H., Madsen, J. and Cariou, B. (2016) Once-Daily Liraglutide versus Lixisenatide as Add-On to Metformin in Type 2 Diabetes: A 26-Week Randomized Controlled Clinical Trial. Diabetes Care, 39, 1501-1509. https://doi.org/10.2337/dc15-2479
|
[23]
|
Dungan, K.M., Povedano, S.T., Forst, T., et al. (2014) Once-Weekly Dulaglutide versus Once-Daily Liraglutide in Metformin-Treated Patients with Type 2 Diabetes (AWARD-6): A Randomised, Open-Label, Phase 3, Non-Inferiority Trial. The Lancet, 384, 1349-1357. https://doi.org/10.1016/S0140-6736(14)60976-4
|
[24]
|
Feher, M., Vega-Hernandez, G., Mocevic, E., et al. (2017) Effectiveness of Liraglutide and Lixisenatide in the Treatment of Type 2 Diabetes: Real-World Evidence from the Health Improvement Network (THIN) Database in the United Kingdom. Diabetes Therapy, 8, 417-431. https://doi.org/10.1007/s13300-017-0241-z
|
[25]
|
Ahmann, A.J., Capehorn, M., Charpentier, G., et al. (2018) Efficacy and Safety of Once-Weekly Semaglutide versus Exenatide ER in Subjects with Type 2 Diabetes (SUSTAIN 3): A 56-Week, Open-Label, Randomized Clinical Trial. Diabetes Care, 41, 258-266. https://doi.org/10.2337/dc17-0417
|
[26]
|
Pratley, R.E., Aroda, V.R., Lingvay, I., et al. (2018) Semaglutide versus Dulaglutide Once Weekly in Patients with Type 2 Diabetes (SUSTAIN 7): A Randomised, Open-Label, Phase 3b Trial. The Lancet Diabetes & Endocrinology, 6, 275-286. https://doi.org/10.1016/S2213-8587(18)30024-X
|
[27]
|
Capehorn, M.S., Catarig, A.M., Furberg, J.K., et al. (2020) Efficacy and Safety of Once-Weekly Semaglutide 1.0 mg vs Once-Daily Liraglutide 1.2 mg as Add-On to 1-3 Oral Antidiabetic Drugs in Subjects with Type 2 Diabetes (SUSTAIN 10). Diabetes & Metabolism, 46, 100-109. https://doi.org/10.1016/j.diabet.2019.101117
|
[28]
|
Buse, J.B., Drucker, D.J., Taylor, K.L., et al. (2010) DURATION-1: Exenatide Once Weekly Produces Sustained Glycemic Control and Weight Loss over 52 Weeks. Diabetes Care, 33, 1255-1261. https://doi.org/10.2337/dc09-1914
|
[29]
|
Buse, J.B., Sesti, G., Schmidt, W.E., et al. (2010) Switching to Once-Daily Liraglutide from Twice-Daily Exenatide Further Improves Glycemic Control in Patients with Type 2 Diabetes Using Oral Agents. Diabetes Care, 33, 1300-1303. https://doi.org/10.2337/dc09-2260
|
[30]
|
Gorgojo-Martínez, J.J., Gargallo-Fernandez, M.A., Brito-Sanfiel, M. and Lisbona-Catalan, A. (2018) Real-World Clinical Outcomes and Predictors of Glycaemic and Weight Response to Exenatide Once Weekly in Patients with Type 2 Diabetes: The CIBELES Project. European Heart Journal, 72, e13055. https://doi.org/10.1111/ijcp.13055
|
[31]
|
Visaria, J., Dang-Tan, T., Petraro, P.V., Nepal, B.K. and Willey, V. (2019) Real-World Effectiveness of Semaglutide in Early Users from a U.S. Commercially Insured (CI) and Medicare Advantage (MA) Population. Diabetes, 68, 1006-P. https://doi.org/10.2337/db19-1006-P
|
[32]
|
Jain, A., Kanters, S., Khurana, R., Kissock, J., Severin, N. and Stafford, S. (2021) Real World Efficacy Analysis of Switch from Liraglutide or Dulaglutide to Semaglutide in Type 2 Diabetes Mellitus: REALiSe-DM Study. Diabetes Therapy, 12, 527-536. https://doi.org/10.1007/s13300-020-00984-x
|
[33]
|
Watanabe, Y., Saisho, Y., Inaishi, J., et al. (2020) Efficacy and Safety of Once Weekly Exenatide after Switching from Twice-Daily Exenatide in Patients with Type 2 Diabetes. Journal of Diabetes Investigation, 11, 382-388. https://doi.org/10.1111/jdi.13146
|
[34]
|
Goncalves, E. and Bell, D.S. (2019) Efficacy of Semaglutide versus Liraglutide in Clinical Practice. Diabetes & Metabolism, 46, 515-517. https://doi.org/10.1016/j.diabet.2019.10.001
|
[35]
|
Overgaard, R.V., Lindberg, S.Ø. and Thielke, D. (2019) Impact on HbA1c and Body Weight of Switching from Other GLP-1 Receptor Agonists to Semaglutide: A Model-Based Approach. Diabetes, Obesity and Metabolism, 21, 43-51. https://doi.org/10.1111/dom.13479
|
[36]
|
Marso, S.P., Daniels, G.H., Brown-Frandsen, K., et al. (2016) Liraglutide and Cardiovascular Outcomes in Type 2 Diabetes. The New England Journal of Medicine, 375, 311-322. https://doi.org/10.1056/NEJMoa1603827
|
[37]
|
Gerstein, H.C., Colhoun, H.M., Dagenais, G.R., et al. (2019) Dulaglutide and Cardiovascular Outcomes in Type 2 Diabetes (REWIND): A Double-Blind, Randomised Placebo-Controlled Trial. The Lancet, 394, 121-130. https://doi.org/10.1016/S0140-6736(19)31149-3
|
[38]
|
Marso, S.P., Bain, S.C., Consoli, A., et al. (2016) Semaglutide and Cardiovascular Outcomes in Patients with Type 2 Diabetes. The New England Journal of Medicine, 375, 1834-1844. https://doi.org/10.1056/NEJMoa1607141
|
[39]
|
Pfeffer, M.A., Claggett, B., Diaz, R., et al. (2015) Lixisenatide in Patients with Type 2 Diabetes and Acute Coronary Syndrome. The New England Journal of Medicine, 373, 2247-2257. https://doi.org/10.1056/NEJMoa1509225
|
[40]
|
Holman, R.R., Bethel, M.A., Mentz, R.J., et al. (2017) Effects of Once-Weekly Exenatide on Cardiovascular Outcomes in Type 2 Diabetes. The New England Journal of Medicine, 377, 1228-1239. https://doi.org/10.1056/NEJMoa1612917
|
[41]
|
Fineman, M.S., Mace, K.F., Diamant, M., et al. (2012) Clinical Relevance of Anti-Exenatide Antibodies: Safety, Efficacy and Cross-Reactivity with Long-Term Treatment. Diabetes, Obesity and Metabolism, 14, 546-554. https://doi.org/10.1111/j.1463-1326.2012.01561.x
|
[42]
|
Bettge, K., Kahle, M., Abd El Aziz, M.S., Meier, J.J. and Nauck, M.A. (2017) Occurrence of Nausea, Vomiting and Diarrhoea Reported as Adverse Events in Clinical Trials Studying Glucagon-Like Peptide-1 Receptor Agonists: A Systematic Analysis of Published Clinical Trials. Diabetes, Obesity and Metabolism, 19, 336-347. https://doi.org/10.1111/dom.12824
|
[43]
|
Nauck, M.A. and Meier, J.J. (2019) Management of Endocrine Disease: Are All GLP-1 Agonists Equal in the Treatment of Type 2 Diabetes? European Journal of Endocrinology, 181, R211-R234. https://doi.org/10.1530/EJE-19-0566
|
[44]
|
Bain, S.C. and McKenna, J. (2010) Clinical Experience with Liraglutide. International Journal of Clinical Practice. Supplement, 167, 44-48. https://doi.org/10.1111/j.1742-1241.2010.02494.x
|
[45]
|
Lin, L.K., Sun, Y., Heng, B.H., Chew, D.E.K. and Chong, P.N. (2017) Medication Adherence and Glycemic Control among Newly Diagnosed Diabetes Patients. BMJ Open Diabetes Research & Care, 5, e000429. https://doi.org/10.1136/bmjdrc-2017-000429
|
[46]
|
Aikens, J.E. and Piette, J.D. (2013) Longitudinal Association between Medication Adherence and Glycaemic Control in Type 2 Diabetes. Diabetic Medicine, 30, 338-344. https://doi.org/10.1111/dme.12046
|
[47]
|
Hamersky, C.M., Fridman, M., Gamble, C.L. and Iyer, N.N. (2019) Injectable Antihyperglycemics: A Systematic Review and Critical Analysis of the Literature on Adherence, Persistence, and Health Outcomes. Diabetes Therapy, 10, 865-890. https://doi.org/10.1007/s13300-019-0617-3
|
[48]
|
Coleman, C.I., Limone, B., Sobieraj, D.M., et al. (2012) Dosing Frequency and Medication Adherence in Chronic Disease. Journal of Managed Care & Specialty Pharmacy, 18, 527-539. https://doi.org/10.18553/jmcp.2012.18.7.527
|
[49]
|
Giorgino, F., Penfornis, A., Pechtner, V., Gentilella, R. and Corcos, A. (2018) Adherence to Antihyperglycemic Medications and Glucagon-Like Peptide 1-Receptor Agonists in Type 2 Diabetes: Clinical Consequences and Strategies for Improvement. Patient Preference and Adherence, 12, 707-719. https://doi.org/10.2147/PPA.S151736
|
[50]
|
Kruk, M.E. and Schwalbe, N. (2006) The Relation between Intermittent Dosing and Adherence: Preliminary Insights. Clinical Therapeutics, 28, 1989-1995. https://doi.org/10.1016/j.clinthera.2006.12.011
|
[51]
|
Qiao, Q., Ouwens, M.J., Grandy, S., Johnsson, K. and Kostev, K. (2016) Adherence to GLP-1 Receptor Agonist Therapy Administered by Once-Daily or Once-Weekly Injection in Patients with Type 2 Diabetes in Germany. Diabetes, Metabolic Syndrome and Obesity, 9, 201-205. https://doi.org/10.2147/DMSO.S99732
|
[52]
|
Nguyen, H., Dufour, R. and Caldwell-Tarr, A. (2017) Glucagon-Like Peptide-1 Receptor Agonist (GLP-1RA) Therapy Adherence for Patients with Type 2 Diabetes in a Medicare Population. Advances in Therapy, 34, 658-673. https://doi.org/10.1007/s12325-016-0470-y
|
[53]
|
Alatorre, C., Fernández Landó, L., Yu, M., et al. (2017) Treatment Patterns in Patients with Type 2 Diabetes Mellitus Treated with Glucagon-Like Peptide-1 Receptor Agonists: Higher Adherence and Persistence with Dulaglutide Compared with Once-Weekly Exenatide and Liraglutide. Diabetes, Obesity and Metabolism, 19, 953-961. https://doi.org/10.1111/dom.12902
|
[54]
|
Mody, R., Huang, Q., Yu, M., et al. (2019) Adherence, Persistence, Glycaemic Control and Costs among Patients with Type 2 Diabetes Initiating Dulaglutide Compared with Liraglutide or Exenatide Once Weekly at 12-Month Follow-Up in a Real-World Setting in the United States. Diabetes, Obesity and Metabolism, 21, 920-929. https://doi.org/10.1111/dom.13603
|
[55]
|
Qin, L., Chen, S., Flood, E., et al. (2017) Glucagon-Like Peptide-1 Receptor Agonist Treatment Attributes Important to Injection-Experienced Patients with Type 2 Diabetes Mellitus: A Preference Study in Germany and the United Kingdom. Diabetes Therapy, 8, 335-353. https://doi.org/10.1007/s13300-017-0237-8
|
[56]
|
Qin, L., Chen, S., Flood, E., et al. (2017) Glucagon-Like Peptide-1 Receptor Agonist Treatment Attributes Important to Injection-Naive Patients with Type 2 Diabetes Mellitus: A Multinational Preference Study. Diabetes Therapy, 8, 321-334. https://doi.org/10.1007/s13300-017-0230-2
|
[57]
|
Gelhorn, H.L., Poon, J.L., Davies, E.W., Paczkowski, R., Curtis, S.E. and Boye, K.S. (2015) Evaluating Preferences for Profiles of GLP-1 Receptor Agonists among Injection-Naive Type 2 Diabetes Patients in the UK. Patient Preference and Adherence, 9, 1611-1622. https://doi.org/10.2147/PPA.S90842
|
[58]
|
Polonsky, W.H., Fisher, L., Hessler, D., Bruhn, D. and Best, J.H. (2011) Patient Perspectives on Once-Weekly Medications for Diabetes. Diabetes, Obesity and Metabolism, 13, 144-149. https://doi.org/10.1111/j.1463-1326.2010.01327.x
|
[59]
|
Thieu, V.T., Robinson, S., Kennedy-Martin, T., Boye, K.S. and Garcia-Perez, L.E. (2019) Patient Preferences for Glucagon-Like Peptide 1 Receptor-Agonist Treatment Attributes. Patient Preference and Adherence, 13, 561-576. https://doi.org/10.2147/PPA.S187907
|
[60]
|
AstraZeneca (2020) BYDUREON Frequently Asked Questions. https://www.bydureon.com/pen/frequently-asked-questions.html
|
[61]
|
Amylin Pharmaceuticals Inc. and Eli Lilly and Company (2006) Byetta Pen User Manual. https://www.accessdata.fda.gov/drugsatfda_docs/label/2006/021773s005lbl.pdf
|
[62]
|
Matfin, G., Van Brunt, K., Zimmermann, A.G., Threlkeld, R. and Ignaut, D.A. (2015) Safe and Effective Use of the Once Weekly Dulaglutide Single-Dose Pen in Injection-Naïve Patients with Type 2 Diabetes. Journal of Diabetes Science and Technology, 9, 1071-1079. https://doi.org/10.1177/1932296815583059
|
[63]
|
European Medicines Agency (2019) Summary of Product Characteristics: OZEMPIC® (Semaglutide). Hyperlink. https://www.ema.europa.eu/en https://www.ema.europa.eu/en/documents/product-information/ozempic-epar-product-information_en.pdf
|
[64]
|
American Diabetes Association (2020) 11. Microvascular Complications and Foot Care: Standards of Medical Care in Diabetes—2020. Diabetes Care, 43, S135-S151. https://doi.org/10.2337/dc20-S011
|
[65]
|
Rodbard, H.W., Lingvay, I., Reed, J., et al. (2018) Semaglutide Added to Basal Insulin in Type 2 Diabetes (SUSTAIN 5): A Randomized, Controlled Trial. The Journal of Clinical Endocrinology & Metabolism, 103, 2291-2301. https://doi.org/10.1210/jc.2018-00070
|